Lerkanidipin Actavis

Lercanidipine hydrochloride, the active ingredient in Lerkanidipin Actavis, is a calcium channel blocker presented as an oral tablet for oral use. It is prescribed to manage hypertension in adult patients and to reduce cardiovascular risk and to reduce cardiovascular risk. It is prescribed under physician supervision through its vasodilatory action in the arterial system.

GNH USA supplies Lerkanidipin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions.

Lercanidipine is a calcium channel blocker used in the management of high‑blood‑pressure conditions.

- Essential hypertension: lowers systolic and diastolic blood pressure, helping to prevent stroke and heart attack. - Isolated systolic hypertension: reduces elevated systolic pressure, particularly in older adults. - Hypertension in elderly patients: provides effective blood pressure control with a favorable tolerability profile.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often occurring after the first dose. - Flushing: sensation of warmth and redness, typically on the face or neck. - Peripheral edema: swelling of the ankles or feet due to fluid accumulation. - Dizziness: light‑headed feeling, especially when standing quickly. - Fatigue: general tiredness that may improve with continued therapy. - Tachycardia: increased heart rate, usually mild.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting or shock. - Myocardial infarction: rare occurrence of heart attack, particularly in patients with existing coronary disease. - Arrhythmias: abnormal heart rhythms that may require medical attention. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes. - Allergic reactions: rash, itching, swelling, or difficulty breathing indicating possible anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Hepatic impairment: use caution and consider dose adjustment in patients with liver dysfunction. - Elderly patients: start at the lowest effective dose and monitor for dizziness or falls. - Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects. - Severe aortic stenosis: contraindicated due to risk of precipitating cardiac failure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension. - Grapefruit juice: can markedly raise lercanidipine levels, leading to enhanced adverse effects. - Other potent antihypertensives: may cause additive blood‑pressure reduction and syncope.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure, diminishing therapeutic effect. - Diuretics: can potentiate orthostatic hypotension; monitor electrolytes and blood pressure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive response; assess renal function regularly.